Jesper Magnusson
Jesper Magnusson
LTx has the shortest survival of all solid organ transplants. The complex and time-demanding diagnostics of allograft dysfunction are a significant reason for this. The current study aims overarchingly to improve survival after lung transplantation (LTx) through precise and fast diagnostics. The specific aim is to develop direct-to-clinical implementation biomarkers for the most important aspects of long-term survival after LTx. An in-house-developed PCR-based cell-free-DNA methodology (cf-DNA) will be used for allograft damage and combined with specific other biomarkers to identify damage type. The current clinical golden standard for damage identification will be performed at every sampling instance. The research will be a single-centre prospective observational cohort study. The control samples at all time points will consist of the samples without allograft damage. Blood will be drawn at fixed time points and clinical events. All analyses will be performed at a separate lab, blinded to the patient's status. .
Lung Transplant Failure and Rejection
Lung Transplant Infection
cell-free dNA
| Study Type : | OBSERVATIONAL |
| Estimated Enrollment : | 146 participants |
| Official Title : | Liquid Biopsies for Lung Allograft Damage Classification |
| Actual Study Start Date : | 2024-12 |
| Estimated Primary Completion Date : | 2029-12 |
| Estimated Study Completion Date : | 2030-12 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 18 Years |
| Sexes Eligible for Study: | ALL |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
No Location Found